Azenta, Inc. (NASDAQ:AZTA) CFO Sells $69,669.60 in Stock

Azenta, Inc. (NASDAQ:AZTA) CFO Herman Cueto sold 1,595 shares of the firm’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total transaction of $69,669.60. Following the completion of the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at approximately $1,074,702.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Azenta Trading Down 0.9 %

Shares of AZTA traded down $0.40 during mid-day trading on Monday, reaching $43.74. 358,300 shares of the stock traded hands, compared to its average volume of 496,392. The firm has a fifty day moving average price of $48.10 and a 200 day moving average price of $51.88. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -16.10 and a beta of 1.47. Azenta, Inc. has a 1 year low of $43.18 and a 1 year high of $69.16.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.09. Azenta had a negative net margin of 23.66% and a positive return on equity of 0.89%. The firm had revenue of $173.00 million during the quarter, compared to analyst estimates of $166.14 million. During the same period in the previous year, the business earned $0.13 EPS. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, sell-side analysts anticipate that Azenta, Inc. will post 0.33 EPS for the current year.

Hedge Funds Weigh In On Azenta

Several hedge funds and other institutional investors have recently modified their holdings of AZTA. Park Avenue Securities LLC increased its position in shares of Azenta by 1.6% during the first quarter. Park Avenue Securities LLC now owns 12,181 shares of the company’s stock valued at $734,000 after buying an additional 192 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in shares of Azenta by 1.7% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,488 shares of the company’s stock valued at $813,000 after buying an additional 229 shares during the period. Arizona State Retirement System increased its position in shares of Azenta by 2.0% during the second quarter. Arizona State Retirement System now owns 14,050 shares of the company’s stock valued at $739,000 after buying an additional 269 shares during the period. Green Alpha Advisors LLC increased its position in shares of Azenta by 3.5% during the third quarter. Green Alpha Advisors LLC now owns 10,203 shares of the company’s stock valued at $494,000 after buying an additional 348 shares during the period. Finally, Handelsbanken Fonder AB increased its position in shares of Azenta by 3.2% during the third quarter. Handelsbanken Fonder AB now owns 12,981 shares of the company’s stock valued at $629,000 after buying an additional 400 shares during the period. 99.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AZTA. Needham & Company LLC reaffirmed a “buy” rating and issued a $69.00 price target on shares of Azenta in a research report on Wednesday, August 7th. Evercore ISI reduced their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Azenta currently has a consensus rating of “Hold” and a consensus price target of $66.40.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.